Articles

Lilly warehouse thieves had security report, lawsuit says

A federal lawsuit contends that thieves who broke into an Eli Lilly and Co. warehouse in Connecticut three years ago and stole more than $60 million worth of drugs obtained a copy of a report that revealed weaknesses in the building's security system.

Read More

House pursues ‘Arkansas model’ on health coverage

Indiana could expand health insurance coverage for low-income Hoosiers entirely through private health insurance plans under an amendment adopted by a House committee on Monday. The change was immediately criticized by the Pence administration.

Read More

J&J wins OK for first in new class of diabetes drugs

Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.

Read More

Crunching the numbers on Obamacare

The biggest changes from President Obama’s 2010 health reform law take effect nine months from now, so many Hoosier employers have started crunching detailed numbers to cost out their options.

Read More

Study: Indiana individual health-claim costs to rise

A study by the nation's leading group of financial risk analysts shows the biggest driver of health insurance premiums will rise by more than 67 percent for Indiana residents' individual policies under President Barack Obama's health care overhaul.

Read More

Deal raises hopes for Healthy Indiana Plan expansion

Gov. Mike Pence’s strategy for expanding Medicaid in Indiana is to convince or cajole the Obama administration to let him use the Healthy Indiana Plan to do it. A recent deal in Arkansas seems to make it more likely that the Obama team will give Pence what he wants.

Read More

Court may decide if drugmakers can pay to delay generics

Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.

Read More